Loading patent…
AssigneeEntasis Therapeutics Limited
InventorsBoudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
Estimating the term…
The present invention is directed to combinations of a β-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of β-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.
A combination consisting essentially of the β-lactamase inhibitor:
A combination consisting essentially of the β-lactamase inhibitor:
A method of treating bacterial infection in a subject in need thereof, consisting essentially of administering to the subject in need thereof an effective amount of the β-lactamase inhibitor:
Dependencies are inferred from the claim text.